Kestra Medical Technologies, Ltd. (KMTS)

Kestra Medical Technologies, Ltd. is a medical device company focused on protecting patients at elevated risk of sudden cardiac arrest. Its main product is the ASSURE system, a wearable cardioverter defibrillator worn as a garment that continuously monitors the heart's rhythm and can automatically deliver a shock if a life-threatening arrhythmia is detected.

The device is typically prescribed for patients during periods of temporary high risk, for example after a heart attack, heart surgery or a new diagnosis of heart failure, while physicians determine whether longer-term therapy is needed. Kestra pairs the device with digital monitoring tools and patient support services, and it is reimbursed largely through insurers and government health programs.

Kestra is headquartered in Kirkland, Washington, and its common stock began trading on the Nasdaq in 2025.